AbbVie and Genmab's Epkinly succeeds in first-line lymphoma trial
AbbVie and Genmab reported that their T-cell engager Epkinly met primary endpoints in a Phase 3 trial for first-line diffuse large B-cell lymphoma, reducing risk of disease progression or death by 51%.
